Trial Profile
Phase IB/IIA Dose-Finding Safety and Activity Study of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) in HIV-Infected Subjects.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Mavorixafor (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 17 Dec 2009 Additional lead trial centrer identified as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 26 Apr 2007 Status changed from recruiting to suspended.